Sign inCreate account

Report workspace

Add to folder
NCT07396818NOT_YET_RECRUITINGanonymous

A Trial of Kamlanoflast In Patients With Amyotrophic Lateral Sclerosis

Sponsor

Source record

Inflammasome Therapeutics

Phase

Source record

Phase 1/2

Modality

AI-normalized

small molecule

Target

AI-normalized

Kamlanoflast is hypothesized to target neuroinflammatory pathways associated with Amyotrophic Lateral Sclerosis (ALS), potentially modulating inflammatory responses and improving functional outcomes in patients.

Indication / condition

AI-normalized

ALS (Amyotrophic Lateral Sclerosis)

Intervention

Source record

Kamlanoflast, Kamlanoflast

Source & freshness

Source record

NCT ID

NCT07396818

Original source

ClinicalTrials.gov

Source last updated

Feb 09, 2026

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07396818

Title

A Trial of Kamlanoflast In Patients With Amyotrophic Lateral Sclerosis

Sponsor

Inflammasome Therapeutics

Status

NOT_YET_RECRUITING

Phase

Phase 1/2

Condition raw

ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Motor Neuron Disease (MND)

Condition normalized

ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Motor Neuron Disease (MND)

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Kamlanoflast is hypothesized to target neuroinflammatory pathways associated with Amyotrophic Lateral Sclerosis (ALS), potentially modulating inflammatory responses and improving functional outcomes in patients.

Target normalized

Kamlanoflast is hypothesized to target neuroinflammatory pathways associated with Amyotrophic Lateral Sclerosis (ALS), potentially modulating inflammatory responses and improving functional outcomes in patients.

Interventions

Kamlanoflast, Kamlanoflast

Public preview

Source record

Kamlanoflast, developed by Inflammasome Therapeutics, is positioned to address a significant unmet need in the ALS market, which currently has limited therapeutic options. The trial aims to assess both safety and efficacy, focusing on inflammatory and functional parameters over a 24-week period. Given the increasing prevalence of ALS and the growing demand for effective treatments, successful outcomes could enhance market access and competitive positioning against existing therapies such as riluzole and edaravone. The estimated enrollment of 40 patients suggests a targeted approach, which may facilitate quicker data generation and regulatory pathways. However, the competitive landscape remains challenging, with ongoing developments in ALS therapies requiring diligent monitoring.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Trial of Kamlanoflast In Patients With Amyotrophic Lateral Sclerosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT07396818

Status

NOT_YET_RECRUITING

Phase

Phase 1/2

Sponsor

Inflammasome Therapeutics

Executive brief

Investment-Ready Snapshot

Kamlanoflast, developed by Inflammasome Therapeutics, is positioned to address a significant unmet need in the ALS market, which currently has limited therapeutic options. The trial aims to assess both safety and efficacy, focusing on inflammatory and functional parameters over a 24-week period. Given the increasing prevalence of ALS and the growing demand for effective treatments, successful outcomes could enhance market access and competitive positioning against existing therapies such as riluzole and edaravone. The estimated enrollment of 40 patients suggests a targeted approach, which may facilitate quicker data generation and regulatory pathways. However, the competitive landscape remains challenging, with ongoing developments in ALS therapies requiring diligent monitoring.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 09, 2026
Internal syncJun 16, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07396818

Indication

ALS (Amyotrophic Lateral Sclerosis)

Modality

small molecule

Target

Kamlanoflast is hypothesized to target neuroinflammatory pathways associated with Amyotrophic Lateral Sclerosis (ALS), potentially modulating inflammatory responses and improving functional outcomes in patients.

Intervention

Kamlanoflast, Kamlanoflast

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.